Tesamorelin + Modified GRF (1-29) + Ipamorelin

1 Identity

Fixed-ratio three-component article containing two GHRH analogues that share A common 29-residue core - a 44-residue N-terminally acylated analogue and a 29-residue tetrasubstituted analogue - plus a five-residue peptide of the GHRP class. The overlap between the two large components is not incidental. It is what makes this article hard to measure, and it governs the analytical design from end to end. "Tesamorelin + Mod GRF 1-29 + Ipamorelin" and "Tesamorelin + CJC-1295 No DAC + Ipamorelin".

Sequence

Per component, cross-referenced. Tesamorelin: trans-3-hexenoyl-YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH2, 44 residues, all-L, one sulfur. Modified GRF (1-29): Y-(D-A)-DAIFTQSYRKVLAQLSARKLLQDILSR-NH2, 29 residues, no sulfur. Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2. Residues 1 TO 29 of the first component and the whole of the second differ at only three positions - 8, 15 and 27 - plus the D-configuration at position 2 and the N-terminal acyl group. Tesamorelin is the active moiety of an approved United States drug product marketed under the brand names EGRIFTA, EGRIFTA SV and EGRIFTA WR, the original approval dating to 10 November 2010 and the WR presentation to 25 March 2025; those brand names are recorded here as identity, because a certificate that names a brand has still not named a sequence.

Molecular formula

Per component; a mixture has no combined formula and none is written. Tesamorelin C221H366N72O67S as the free base, supplied as the acetate with x approximately 7. Modified GRF (1-29) C152H252N44O42, no sulfur. Ipamorelin C38H49N9O5 as the free base, mono-acetate C40H53N9O7. Total sulfur is A clean stoichiometric proxy for tesamorelin alone: one sulfur per mole in the 44-mer, none in either other component, and it is the only elemental handle this article offers.

Average mass

Per component, on IUPAC 2021 abridged conventional atomic weights: tesamorelin 5,135.856 Da free base; Modified GRF (1-29) 3,367.954 Da; ipamorelin 711.868 Da. At a nominal 5 mg plus 5 mg plus 5 mg fill, 15 mg total, the 1.0 : 1.0 : 1.0 mass ratio is a molar ratio of 1.00 : 1.52 : 7.21 - 0.97355, 1.48458 and 7.02377 micromol. The two large components are 1,767.902 Da apart, which is the separation any mass-based quantitation of this article rests on, and it is comfortably wide; the difficulty lies entirely in the amino acid composition, not in the mass. That fill is a stated nominal used for the arithmetic and not a market standard.

Monoisotopic mass

Per component. Tesamorelin 5,132.71664 Da neutral, used with a deconvoluted charge envelope. Modified GRF (1-29) 3,365.89358 neutral, [M+3H]3+ 1,122.97180, [M+4H]4+ 842.48067. Ipamorelin 711.3857, [M+H]+ 712.3930. Three separations govern identity: the des-acyl 44-mer at minus 96.058 Da; sermorelin at 3,357.933, which sits 10.021 Da from the tetrasubstituted analogue and carries a sulfur that analogue lacks; and CJC-1295 (DAC:GRF) at 3,647.250, 279.296 Da from it. A single blend "molecular weight" is never printed, because a mixture does not have one.

Salt / variant note

The internal ambiguity is the one PECULIAR to this article: the two large components share twenty-nine positions and differ at three, so a lot made with the wrong ratio of the two, or with one substituted for part of the other, is not detectable on total peptide content, on total amino acid composition without a chiral step, or on any single-component identity test. Then the external confusables. Sermorelin at 3,357.933 shares residues 1 to 29 with tesamorelin exactly and is 10.021 Da from Modified GRF (1-29). CJC-1295 (DAC:GRF) at 3,647.250 is the molecule the second market title wrongly implies. Two species are degradants rather than variants and are specified as such: the des-acyl 44-mer at minus 96.058 Da, and methionine sulfoxide at plus 15.995 Da, which can only arise from tesamorelin here. Salt form is stated per component rather than for the vial: tesamorelin as the acetate, ipamorelin as the free base or the mono-acetate. Ratio: 5 mg / 5 mg / 5 mg is a stated nominal and no ratio is standard.

2 Class & testing panel

Form

Fixed-ratio blend

Testing panel

P2 and P3 — panel definitionas A union, run on every component separately and never once on the vial. P2 carries the acylated 44-mer, adding hexenoyl-group integrity and the des-acyl species. P3 carries Modified GRF (1-29)'s D-Ala2 and ipamorelin's Aib1, D-2-Nal3 and D-Phe4. Each component is released against its full single-article panel on the input material before blending; the finished article is then released against the blend criteria, per-component net content and every pairwise ratio included. The panels themselves are defined on the Testing Standard page. The chiral method carries unusual weight on this article, and the reason is the residue overlap. Modified GRF (1-29) shares every residue type with tesamorelin, so conventional amino acid analysis cannot resolve the two, and this is the article in which no component has a unique marker residue at all. The method file therefore names the chiral D-alanine route and quantitative LC-MS instead of asserting a marker. An authentic reference standard is publicly procurable for one of the three components only, which is a second reason identity rests on the chiral step and on quantitative LC-MS rather than on standard comparison alone

3 Primary sources & evidence

The index reports the design and provenance of the literature, not a conclusion about effect.

Published literature exists for each component and is cross-referenced from that component's record rather than restated here. The tesamorelin file rests on registrational trials, by identifier: Falutz et al., N Engl J Med 2007;357:2359-2370, PMID 18057338, DOI 10.1056/NEJMoa072375, n=412, 26 weeks; and Falutz et al., J Clin Endocrinol Metab 2010;95:4291-4304, PMID 20554713, DOI 10.1210/jc.2010-0490, pooled, n=806. The Modified GRF (1-29) file is thin under that designation and traces to the Salk substitution chemistry of the 1980s and 1990s, with no registered controlled human trial identified. The ipamorelin file is preclinical in substance. No published study of this fixed three-component combination at any ratio has been identified, and that is a statement about the search, not a finding about the article.

4 Storage & specification

Storage

Co-lyophilized solid held at -20 degrees C plus or minus 5 degrees C, desiccated and protected from light, in amber glass with the headspace displaced with nitrogen and re-blanketed after subdivision. A non-sterile laboratory chemical, no sterility claim, no injection format. Four degradation points make those conditions a specification rather than housekeeping: the N-terminal hexenoyl amide is the hydrolysis-sensitive point in solution; the single methionine is the oxidation-sensitive point in both the solid and the solution state; aspartimide formation at Asp3 and Asp25 is the principal solid-state route on the tetrasubstituted analogue, which has no methionine to lose; and the naphthalene ring of ipamorelin makes the solid photosensitive.

Shelf life

Provisional 24 months at -20 degrees C plus or minus 5 degrees C, desiccated and protected from light, from the date of QA release. The interval is taken as the shortest of the three component intervals, each itself a provisional 24 months. Des-acyl content, methionine sulfoxide and iso-aspartate are the attributes that limit retest, rather than peptide-backbone degradation.